News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
566,084 Results
Type
Article (45670)
Company Profile (120)
Press Release (520294)
Multimedia
Podcasts (82)
Webinars (12)
Section
Business (155428)
Career Advice (2411)
Deals (29038)
Drug Delivery (120)
Drug Development (71293)
Employer Resources (151)
FDA (15845)
Job Trends (12477)
News (278960)
Policy (30549)
Tag
Academia (2369)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (82)
Alliances (37008)
ALS (89)
Alzheimer's disease (1454)
Antibody-drug conjugate (ADC) (138)
Approvals (15801)
Artificial intelligence (246)
Autoimmune disease (27)
Automation (12)
Bankruptcy (318)
Best Places to Work (9663)
BIOSECURE Act (22)
Biosimilars (114)
Biotechnology (72)
Bladder cancer (80)
Brain cancer (27)
Breast cancer (268)
Cancer (2177)
Cardiovascular disease (190)
Career advice (2015)
Career pathing (33)
CAR-T (144)
Cell therapy (418)
Cervical cancer (20)
Clinical research (57979)
Collaboration (727)
Compensation (530)
Complete response letters (29)
COVID-19 (2643)
CRISPR (43)
C-suite (225)
Cystic fibrosis (97)
Data (2075)
Decentralized trials (2)
Denatured (14)
Depression (53)
Diabetes (272)
Diagnostics (5488)
Digital health (15)
Diversity (4)
Diversity, equity & inclusion (42)
Drug discovery (104)
Drug pricing (122)
Drug shortages (30)
Duchenne muscular dystrophy (97)
Earnings (66411)
Editorial (44)
Employer branding (20)
Employer resources (136)
Events (91815)
Executive appointments (661)
FDA (17085)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (655)
Gene editing (105)
Generative AI (22)
Gene therapy (320)
GLP-1 (799)
Government (4145)
Grass and pollen (6)
Guidances (61)
Healthcare (15612)
Huntington's disease (24)
IgA nephropathy (29)
Immunology and inflammation (141)
Indications (26)
Infectious disease (2789)
Inflammatory bowel disease (134)
Inflation Reduction Act (9)
Influenza (49)
Intellectual property (89)
Interviews (450)
IPO (14562)
IRA (48)
Job creations (3201)
Job search strategy (1672)
Kidney cancer (11)
Labor market (32)
Layoffs (512)
Leadership (23)
Legal (7184)
Liver cancer (73)
Lung cancer (310)
Lymphoma (149)
Machine learning (7)
Management (51)
Manufacturing (295)
MASH (71)
Medical device (11602)
Medtech (11605)
Mergers & acquisitions (14990)
Metabolic disorders (735)
Multiple sclerosis (79)
NASH (22)
Neurodegenerative disease (101)
Neuropsychiatric disorders (33)
Neuroscience (2001)
NextGen: Class of 2025 (5205)
Non-profit (3377)
Now hiring (18)
Obesity (405)
Opinion (224)
Ovarian cancer (69)
Pain (89)
Pancreatic cancer (78)
Parkinson's disease (150)
Partnered (16)
Patents (231)
Patient recruitment (100)
Peanut (45)
People (44253)
Pharmaceutical (35)
Pharmacy benefit managers (21)
Phase I (17209)
Phase II (25201)
Phase III (20523)
Pipeline (1192)
Policy (166)
Postmarket research (2377)
Preclinical (7135)
Press Release (37)
Prostate cancer (110)
Psychedelics (36)
Radiopharmaceuticals (222)
Rare diseases (399)
Real estate (4409)
Recruiting (60)
Regulatory (21406)
Reports (32)
Research institute (2101)
Resumes & cover letters (402)
Rett syndrome (4)
RNA editing (3)
RSV (47)
Schizophrenia (77)
Series A (122)
Series B (80)
Service/supplier (10)
Sickle cell disease (54)
Special edition (16)
Spinal muscular atrophy (132)
Sponsored (33)
Startups (2825)
State (1)
Stomach cancer (16)
Supply chain (72)
Tariffs (45)
The Weekly (67)
Vaccines (771)
Venture capitalists (43)
Weight loss (295)
Women's health (31)
Worklife (20)
Date
Today (195)
Last 7 days (862)
Last 30 days (2540)
Last 365 days (30647)
2025 (10254)
2024 (32371)
2023 (36361)
2022 (46517)
2021 (50204)
2020 (47190)
2019 (38128)
2018 (28869)
2017 (28820)
2016 (27344)
2015 (30615)
2014 (24114)
2013 (19572)
2012 (21041)
2011 (21512)
2010 (19458)
Location
Africa (682)
Alabama (47)
Alaska (6)
Arizona (179)
Arkansas (10)
Asia (32409)
Australia (5667)
California (5705)
Canada (1612)
China (433)
Colorado (243)
Connecticut (272)
Delaware (134)
Europe (78621)
Florida (852)
Georgia (188)
Hawaii (1)
Idaho (39)
Illinois (461)
India (24)
Indiana (261)
Iowa (11)
Japan (150)
Kansas (85)
Kentucky (13)
Louisiana (7)
Maine (62)
Maryland (855)
Massachusetts (4298)
Michigan (189)
Minnesota (344)
Mississippi (1)
Missouri (73)
Montana (12)
Nebraska (19)
Nevada (57)
New Hampshire (53)
New Jersey (1620)
New Mexico (15)
New York (1601)
North Carolina (920)
North Dakota (6)
Northern California (2530)
Ohio (163)
Oklahoma (8)
Oregon (28)
Pennsylvania (1244)
Puerto Rico (10)
Rhode Island (21)
South America (1048)
South Carolina (21)
South Dakota (1)
Southern California (2149)
Tennessee (87)
Texas (799)
United States (21259)
Utah (160)
Virginia (135)
Washington D.C. (60)
Washington State (515)
West Virginia (3)
Wisconsin (54)
566,084 Results for "recordati s p a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
April 16, 2025
·
7 min read
Press Releases
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
April 29, 2025
·
6 min read
Press Releases
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
February 13, 2025
·
11 min read
Press Releases
Recordati Announces Agreement to Acquire the Global Rights to Enjaymo®, Strengthening Its Rare Diseases Franchise
October 4, 2024
·
5 min read
Rare diseases
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.
October 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%
November 11, 2024
·
21 min read
Press Releases
Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors
April 21, 2025
·
4 min read
Press Releases
David P. King Joins Truvian’s Advisory Board
January 13, 2025
·
2 min read
Press Releases
Acadia Pharmaceuticals Set to Join S&P SmallCap 600
December 31, 2024
·
1 min read
Press Releases
Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A
January 14, 2025
·
4 min read
1 of 56,609
Next
